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Abstract
Cadherins are a large family of Ca2+dependent adhesion proteins. They are transmem‐
brane or closely related to membrane glycoproteins localized in specialized adhesive
junction.  The  expression  of  various  cadherins  may  be  concomitant  with  cancer
progression steps and the term ‘cadherin switch’ has been created due to the observation
of down‐regulation of E‐cadherin (suppressor of metastatic potential) and up‐regula‐
tion  of  N‐cadherin  (promoter  of  metastatic  potential)  expression  during  tumour
progression. These changes are thought to be closely related to epithelial‐to‐mesenchy‐
mal transition of cells of many different types of cancer including skin cancers, and
accompany the increase of their motility and invasion abilities resulting in the metastasis
formation.  The  cadherin  polypeptide  is  a  potential  substrate  for  post‐translational
modification, for example, N‐glycosylation, and its important role in the regulation of
cadherin function has been described. The changed glycosylation of cadherins has been
described  in  various  skin  cancers  including  melanoma  and  was  consistent  with
cadherins’  role  in  epithelial‐to‐mesenchymal  transition.  The  detailed  analysis  of
cadherin expression and cadherin‐related glycosylation changes taking place during
malignant transformation could be a key for better understanding of the nature of this
process and may open new opportunities for the creation of more effective anticancer
therapeutics and diagnostic tools.
Keywords: cadherins, melanoma, basal cell carcinoma, squamous cell carcinoma, gly‐
cosylation, metastasis
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1. Introduction
In  humans,  cadherins  comprise  a  superfamily  of  over  100  calcium‐dependent  adhesion
molecules  that  play fundamental  roles  in  supervising morphogenetic  and differentiation
processes during development, and in maintaining tissue architecture and homeostasis [1].
Therefore, their expression is tightly regulated during development, and abnormalities in the
expression or function of cadherins are characteristic features of transformed cells. Being
transmembrane  proteins,  cadherins  are  built  from  extracellular,  transmembranous  and
cytoplasmic domains.  The only exception is an unusual T (truncated)‐cadherin, which is
similar to the classical cadherins in terms of ectodomain construction, but differs from them
by lacking both the transmembrane and cytoplasmic domains. Instead, T‐cadherin is linked
to plasma membrane through a glycosylphosphatidylinositol (GPI) anchor [2]. Extracellular
domain  of  T‐cadherin  lacks  many  amino  acids,  which  are  responsible  for  the  adhesive
function of the classical cadherins. Therefore, it is suggested that T‐cadherin functions as a
signalling molecule rather than as a cell adhesion molecule [3].
According to the sequence similarity, cadherins have been divided into five subfamilies:
classical types I and II (E‐, P‐, N‐ and VE‐cadherin), atypical (T‐cadherin), desmosomal
(desmogleins, desmocollins), protocadherins and cadherin‐related proteins [4]. Cadherins
maintain stable cell‐cell adhesion via homophilic interactions of their extracellular regions that
trigger the assembly of specialized adhesive junctions (AJs) known as desmosomes and
adherens junctions, and tethering the microfilaments and intermediated filaments to the
plasma membrane by the cytoplasmic domains [5]. In this way, cadherins, by mediating
adhesion, provide a cohesion and communication between cells in a tissue [1]. The cytoplasmic
region anchors cadherin to actin cytoskeleton via interaction with catenin family—β‐catenin,
γ‐catenin, which binds directly to cadherin tail, and α‐catenin, which links β‐ or γ‐catenin to
actin.
β‐catenin is attached to cadherin in the endoplasmic reticulum at the early stage of its targeting
to the plasma membrane, where they are present as a complex. Therefore, this cadherin‐β‐
catenin interaction is independent of cadherin engagement in adhesion [6]. α‐catenin has been
perceived as a constituent stably binding the β‐catenin‐cadherin complex to actin cytoskeleton,
but it has been shown nowadays that allosteric character of α‐catenin indisposes its binding
to β‐catenin and F‐actin at the same time [7]. Another member of the catenin family, p120‐
catenin, attaches to the cadherin‐catenin complex in the plasma membrane and controls
cadherin turnover by stabilization of the complex assembly at the plasma membrane. p120‐
catenin knockdown experiments with the use of RNAi have shown a more rapid turnover and
degradation of cadherin complexes [8]. β‐catenin and p120‐catenin are substrates of tyrosine
kinase receptor, and therefore the adhesion could be regulated by the action of growth factors
[9]. Clustering of AJs results in remodelling of the actin cytoskeleton [10–13]. There is a wide
variety of proteins associated with cadherins and this association is thought to be transient
and adjustable dependent on cell context and the triggered cellular‐signalling pathways [14].
First reports of Ca2+‐dependent surface glycoproteins mediating intercellular adhesion have
regarded chick development and process of morula compaction in pre‐implantation mouse
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embryo [15–18]. The first identified, E‐cadherin is a classical type I cadherin, and its prefix ‘E’
refers to the epithelial cells (ECs) where it was originally described. Other classical cadherins
of a different spatiotemporal expression pattern include N‐cadherin (neural, type I), P‐
cadherin (placenta, type I) [19], R‐cadherin (retina, type I) [20] and VE‐cadherin (vascular
endothelial, type II) [21].
The structure of classic cadherin molecules is more or less conserved; they possess a cytoplas‐
mic domain associated with the armadillo proteins family [22], and in the case of E‐cadherin
this region comprises 150 aa [4]. Next, there is a single‐pass transmembrane region, and
extracellular domain of 550 aa, which in classic cadherins (types I and II), desmosomal and T‐
cadherin contain five segments of a repeated sequence. The extracellular domains are num‐
bered from EC1 to EC5, where the sequence of the headmost EC5 is characteristic because of
the presence of four conserved cysteine residues [4, 23, 24]. In the extracellular domain between
the adjacent EC domains, the highly conserved Ca2+‐binding sequences are located.
Based on E‐cadherin structure analysis, several possible mechanisms of cadherin‐mediated
cell‐cell adhesion have been proposed. Cadherins could form either trans dimers, where the
linkage is formed by cadherins from apposed cells, or cis dimers, where the lateral interaction
between cadherin molecules in the same cell membrane takes place. Their formation depends
on Ca2+ availability. In Ca2+ presence, trans dimers are formed preferentially, while in its absence
cis dimer formation predominates. Furthermore, trans dimers are thought to be responsible
for cell‐cell adhesion, and the formation of cis dimers has been reported to enhance the strength
of adhesive interaction [11, 25]. Both dimers are formed via the same region of cadherin
molecules—EC1 domain; however, the involvement of EC3 domain has also been confirmed
in the case of trans dimerization process. Concerning EC1 and EC3 role in trans dimerization,
three possible adhesive antiparallel alignments have been proposed, starting from the
outermost adhesive bonds between EC1 domains, through middle bond requiring both EC1
and EC3 contribution in bond formation, and finally the innermost adhesive bounds formed
by the EC3 domains [26]. The classic model assumed that there are homophilic interactions
between cadherins, but growing evidence suggests also the presence of heterophilic ones. Shan
and co‐workers have reported heterophilic interactions between R‐ and N‐cadherins interact‐
ing either in cis or in trans manner [25]. Importantly, cadherins can be post‐translationally
modified by phosphorylation, O‐glycosylation but the most prominent modification is N‐
glycosylation [10, 27–29].
2. Cadherins and skin cancers
It is well known that the transformation of normal tissue cells to tumour cells is associated
with the changes in the repertoire of cell‐surface adhesions, such as cadherins, and carbohy‐
drate structures are attached to them. Altered glycosylated cell‐surface glycoproteins influence
the growth, proliferation and survival of tumour cells, and facilitate their migratory and
invasion behaviour, formation of distant metastases as well as the induction of immunosup‐
pression. It is noteworthy that tumour‐associated antigens can serve as valuable diagnostic
and therapeutic targets.
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Skin tumours comprise melanoma and non‐melanoma skin cancers. Non‐melanoma neo‐
plasms are mainly divided into basal cell carcinoma (BCC), squamous cell carcinoma (SCC),
keratoacanthoma (KA, a benign low‐grade skin tumour without the competence to metastasize
or invade), trichoepithelioma (TE, a benign skin tumour, which arises from the hair germ),
actinic keratosis (AK, a precancerous stage of squamous cell carcinoma) and Merkel cell
carcinoma (MCC, an early metastasizing neoplasm of high‐grade malignancy). Although
melanoma is much less common, it possesses high potential to invade surrounding tissues and
very quickly develops distant metastases. Therefore, melanoma is the leading cause of deaths
from skin cancer.
2.1. Cadherins in the skin
In human skin, the expression of several cadherin molecules, belonging to all five major groups
of the cadherin family, has been described. The changes in their protein levels have been
extensively investigated regarding the developmental processes and neoplastic transforma‐
tion of skin cells (Table 1). The vast majority of research studies concern classical cadherins.
Both E‐ and P‐cadherins are the major components of the intercellular AJs of the epidermis [30],
and they are main players in morphogenesis and in maintaining the structure of the skin.
Referring to E‐cadherin, the wide distribution of its expression in all skin layers and in skin
appendages has been shown, and its role in keratinocytes‐melanocytes adhesion and commu‐
nication has been established. It has been reported that E‐ and N‐cadherin‐negative dermal
stem cells (DSCs), isolated from human foreskin dermis during their differentiation into
melanocytes and migration to the epidermis, gain E‐cadherin expression, enabling them to
interact with the keratinocytes [31]. On the other hand, in vitro experiments in melanocytes
and keratinocytes co‐cultures have shown that during wound healing and re‐pigmentation
process, diminished E‐cadherin expression in melanocytes increases their migration capacity
as they migrate much faster than keratinocytes into the wound area [32].
The expression of P‐cadherin, which is known to be indispensable for proper skin and eye
function, has been more diversified and dependent on the skin layer. It is mainly present in
the basal and lower suprabasal layers, where it was linked with the proliferative compartment
of the epidermis. The predominant expression of P‐cadherin has also been observed in the
growing hair follicle, where it has an important role in its differentiation. Moreover, P‐cadherin
has been suggested to have a regulatory effect on melanogenesis, mainly due to the inhibition
of tyrosinase activity, and to regulate melanosome transport within the melanosome unit [24].
The expression of N‐cadherin has also been described in the skin during developmental
processes, referring to dermal fibroblasts and endothelial cells but not in keratinocytes or
melanocytes [33]. N‐cadherin expression has been analysed in murine model of melanocytes
development and in vitro cultured melanoblast, melanocyte and melanoma cell lines. The
melanoblasts/melanocytes of a 3‐day‐old mouse dermis have expressed only small amount of
N‐cadherin, while its significantly higher expression has been reported in all in vitro models
[34]. The changed expression of N‐cadherin on dermal melanocytes has been suggested to
enable their migration during developmental processes and stabilized their interaction with
dermal fibroblasts [35].
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aAntibody staining/cadherin expression level in human keratinocytes, BCC, SCC and in human melanocytes and
melanoma cells, respectively, described by the colour‐coding scales:  /  high,  /  medium,  /  low,  /  not
detected. The numbers within bars correspond to the percentage of a given staining/cadherin expression level. Data for
protocadherins γ 2‐12 of subfamily A, protocadherins γ 1,2,4‐7 of subfamily B and protocadherins γ 3‐5 of subfamily C
have not been analysed due to the antibodies that cross‐reacted with multiple isoforms. Data are based on The Human
Protein Atlas (www.proteinatlas.org).
bSchematic structure of a representative member of the given cadherin subfamily.
BCC, basal cell carcinoma; K, keratinocyte; M, melanocyte; and SCC, squamous cell carcinoma; C, COOH terminus of
protein; CBD, β‐catenin‐binding domain or plakoglobin‐binding domain in the case of desmosomal cadherins; CE,
cysteine‐rich EGF‐repeat‐like domain; CM1‐3, conserved motifs in the cytoplasmic domains of nonclustered δ‐
protocadherins; EC, extracellular cadherin repeats; GPI, glycosylphosphatidylinositol anchor; JMD, juxtamembrane
domain with p120‐catenin‐binding site; LAG, laminin‐A globular domain‐like domain; N, NH2‐terminus of protein;
ProP, propeptide; RUD, intracellular repeated unit domain of desmosomal cadherins; SP, signal peptide; TM,
transmembrane domain; and UCD, unique cytoplasmic domain.
Table 1. Comparison of the expression pattern of cadherins in keratinocytes versus BCCs and SCCs, and melanocytes
versus melanoma cells.
In normal skin, the expression of T‐cadherin is mostly limited to melanocytes and actively
proliferating keratinocytes of the basal layer, as well as to a lesser extent to dermal blood
vessels. Unlike other cadherins, T‐cadherin molecules are anchored in lipid rafts dispersed on
the whole cell plasma membrane [36].
The changes in the expression level of particular cadherins, named ‘cadherin switch’, con‐
cerning the down‐regulation of E‐cadherin expression mediating strong adhesion signal, and
recognized as an invasion suppressor, and the up‐regulation of N‐cadherin expression
inducing more motile and invasive phenotype of cells have been suggested either during
development or in cancer, where it may be concomitant with cancer progression steps [37–
39]. The ‘cadherin switch’ has been observed and described as an indispensable step, enabling
the epithelial‐to‐mesenchymal transition (EMT).
2.2. Role of cadherins in epithelial-to-mesenchymal transition
EMT is a process of dedifferentiation, which has been described by three major cell pheno‐
type changes, including (1) diminution of cellular adhesion, as an effect of changes in the
expression of adhesion receptors and cytoskeletal proteins; (2) loss of epithelial cell polarity
accompanied by morphological changes leading from the cobblestone‐like epithelial cells to
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spindle‐shaped mesenchymal cells; and (3) the acquisition of more motile and invasive be‐
haviour [40, 41]. This process takes place during normal embryonic development as a basic
step of tissue remodelling, such as mesoderm formation and neural crest development. It
should be noted that the reverse process, named mesenchymal‐to‐epithelial transition
(MET), also occurs evidencing the enormous plasticity of developmental processes [40].
EMT‐like processes are observed also in the course of wound healing, during which in re‐
sponse to injury keratinocytes go through a ‘metastable’ phenotype by losing their contact
and therefore move [42]. EMT has been suggested in numerous cancer types, including mel‐
anoma and supposed as a conducive to metastasis formation.
2.2.1. EMT molecular markers
Besides or as a consequence of EMT‐related ‘cadherin switch’, more abundant expression of
vimentin with simultaneous β‐catenin translocation to the nucleus, and increased expression
of transcription factors such as Slug, Snail, Twist, EF1/ZEB1, SIP1/ZEB2 and E47 have been
observed. They are reported as markers of developmental processes [43–45] and skin cancer
cells transformation [38, 46, 47]. It is noteworthy that the suggestion is made on the basis of
metastatic BCC observations that the enhanced Twist1 expression may serve as a biomarker
of BCC progression [48]. Immunohistochemical analysis of tissue sections of non‐metastasiz‐
ing, metastasizing and lymph node metastasis of cutaneous SCC (cSCC) has revealed that their
metastatic potential is accompanied by EMT‐marker expression, including the Twist overex‐
pression, while in metastases the expression of selected EMT‐related markers has been
decreased [49]. Also, the increased expression of other EMT‐related markers such as Ki‐67 and
keratin 17, together with the reduced expression of both E‐cadherin and involucrin (early
marker of epidermis keratinocytes differentiation), has been shown in the cSCC compared to
normal skin biopsies [50].
Some studies suggested that the EMT is closely related with the cancer stem cells (CSCs)
biology, and therefore the analysis of expression of CD44 and CD29 (β1‐integrin subunit)
recognized as CSCs markers has been conducted in cSCC A341 cells. High expression of both
markers has been described in cells located in the periphery of cSCC tumours. Simultaneously,
a higher N‐cadherin and a lower E‐cadherin expression have been detected in CD44+/CD29+
cells, legitimizing their EMT [51]. In human, BCC analysis of paraffin‐embedded tissue sections
suggested strong correlation between tumour progression and the expression of integrin‐
linked kinase (ILK), which has been proposed there as an EMT marker [52].
The expression of EMT markers has been analysed in desmoplastic melanoma (DM) tumours,
which makes diagnostic difficulties because of its unusual clinical appearance. These are
mainly amelanotic, deep cutaneous tumours surrounded by sun‐damaged skin [53]. The
comparison of EMT markers expression profile conducted in tissue microarrays of DM and
primary vertical growth phase non‐desmoplastic melanomas (NDMs) has demonstrated a
significantly higher expression of EMT‐related proteins—N‐cadherin, SPARC and WT‐1, and
the decreased expression of E‐cadherin in DM compared to NDM, suggesting usefulness of
these markers in DM diagnostics [54].
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Another known marker of EMT and tumour metastasis is the elevated expression of N‐
acetylglucosaminyltransferase V (GnT‐V) responsible for β1,6‐branching of N‐linked
complex‐type oligosaccharides. In cutaneous wound healing of GnT‐V transgenic mice, GnT‐
V‐overexpressed keratinocytes showed spindle‐shaped morphology and enhanced
migration, which were associated with the early phase of malignant transformation: changes
in E‐cadherin glycosylation and localization as well as induction of EMT. As a result, EMT‐
associated factors Snail and Twist were up‐regulated, and cadherin switch was observed
[55].
2.2.2. EMT-initiating factors
EMT initiation has been attributed to a variety of growth factors, including members of the
epidermal growth factor (EGF), the fibroblast growth factor (FGF) and the insulin‐like growth
factor (IGF) families, hepatocyte growth factor (HGF) and transforming growth factor‐β (TGF‐
β). The intracellular‐signalling pathways, induced by these growth factors, have led to
characteristic transformation from epithelial, differentiated and proliferative phenotype to
mesenchymal, dedifferentiated ready to migration and invasion phenotype. Down‐regulated
dermal fibroblast secretion of HGF caused by knockdown of RaIA GTPase expression (known
contributor in Ras‐induced tumourigenesis) has resulted in the suppression of SCC tumour
progression. As an effect, the reduced migratory abilities of neighbouring keratinocytes,
related to the changes in expression levels of E‐cadherin (increased) and transcription factors
—Snail and Slug—suppressing E‐cadherin RNA level, have been observed [56]. The TGF‐β‐
induced EMT has been observed in melanoma cells and accompanied by the activation of the
PI3K and platelet‐derived growth factor (PDGF)‐signalling pathways triggering the up‐
regulation of N‐cadherin expression and the transformation of a proliferative phenotype of
cells into a more invasive one [57].
The involvement of PI3K/AKT‐signalling pathway has also been suggested in EMT of SCC
cells. The analysis of isogenic cell lines derived from succeeding stages of keratinocytes
malignant transformation, that is, dysplastic forehead skin (PM1), primary cSCC (MET1) and
its lymph node metastasis (MET4), has shown the correlation between tumour progression
and the activation of AKT. Additionally, it has been reported that the inhibition of AKT activity
results in the decreased cell migration and invasion, reduced cell detachment and reduced
expression of EMT markers such as Slug and vimentin concomitantly with the up‐regulation
of E‐cadherin expression [46].
There are also some data concerning the relevance of cytokine IL‐6 secretion during the
inflammatory processes for the initiation of EMT and subsequent malignant transformation
of normal human keratinocytes of HaCat cell line. In response to arsenite treatment, the
elevated IL‐6 secretion has been observed leading to the increased level of miR‐21, microRNA
related with the malignancies and overexpressed in most cancers. The arsenite‐transformed
HaCat cells have shown the changed expression level of E‐cadherin (decreased) and vimentin
(increased), which was linked with the initiation of EMT process and increased migration
capacity of transformed cells [58]. As melanoma patients are characterized by a higher IL‐6
serum level, its important role in the stimulation of melanoma progression has been suggested.
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In a mouse melanoma model, the action of IL‐6 has led to the increased metastatic potential
due to up‐regulation of Twist expression and subsequent N‐cadherin overexpression. Thus,
therapies directed specifically against IL‐6 could possibly reduce the tumour progression [59].
In response to mechanical tissue damage, and succeeding action of cytokines and growth
factors (TGF‐β, EGF), the activation of specific signalling pathways has been reported in skin
keratinocytes, leading to the activation of Snail—a regulator of keratinocytes inflammatory
response and an EMT marker. Snail protein acts as gene transcription repressors, and E‐
cadherin gene has been recognized as its prototypic target. Down‐regulated E‐cadherin
expression facilitates the process of wound healing by losing adhesion between keratinocytes,
EMT promotion and subsequent keratinocyte migration. Likewise, in the course of keratino‐
cyte neoplastic transformation, signalling via Snail promotes migration and invasion pheno‐
type, proinflammatory microenvironment and degradation of extracellular matrix
characteristic for SCC [60]. These processes are similar in many carcinoma types and sugges‐
tion has been made that tumours resemble wounds that do not heal [61].
2.3. Cancer-related changes in cadherin expression
While the neoplastic transformation of many cell types is accompanied by the loss of or
disturbances in gap junction formation, the neoplastic transformation of melanocytes and
keratinocytes follows the same path. It has been observed that the diminished E‐cadherin
expression level, typical for melanoma cells, disturbs their interaction with adjacent keratino‐
cytes and therefore prevents the regulating influence of keratinocytes on the melanoma cells
growth and differentiation [62]. The large body of evidence has suggested that melanoma cells
transformation from non‐malignant to invasive ones is accompanied by the loss of E‐cadherin
and overexpression of N‐cadherin. It has been suggested, however, that not N‐cadherin itself
had been responsible for the start of melanoma cells dissemination and metastasis formation
[63]. Observations have revealed that the deregulation of E‐ and N‐cadherin expression is
involved in tumourigenesis and cancer progression also in other skin cancers—MCC, SCC and
BCC [52, 58, 64, 65].
2.3.1. E-cadherin
The important role of E‐cadherin expression for the malignant transformation of melanoma
cells and SCC has been confirmed in numerous tissue samples assembled in tissue microarrays
of human malignant melanoma and SCC as well as in selected cell lines, including A375, SK‐
MEL‐24, MV3 and M14 melanoma cell lines. As a conclusion of this analysis, Tang et al. [66]
have postulated the reverse correlation between the E‐cadherin expression level and the
expression of ubiquitin protein ligase E3C (UBE3C), which positively regulates tumour growth
and metastasis by inducing the mesenchymal phenotype of melanoma cells. In melanoma, E‐
cadherin expression has been also shown to be correlated with the altered expression of
microRNA (miRNA). Analysis of frozen melanoma tissue section demonstrated that the
decreased expression of mi‐R200a, mi‐R200c, and miR‐203, previously described as contribu‐
tors of melanoma metastasis, correlated with down‐regulation of E‐cadherin and growing
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tumour thickness. These data reveal miRNA role in the regulation of E‐cadherin expression in
the course of melanoma progression [67].
α‐catulin is a cytoplasmic molecule, overexpressed in melanoma that has been recognized as
a negative regulator of E‐cadherin expression, consequently promoting melanoma progres‐
sion. It has been confirmed in α‐catulin knockdown experiments, where the enhanced
melanoma cells binding to keratinocytes as well as up‐regulated E‐cadherin expression have
been observed resulting in the lower migratory and invasive potential of melanoma cells [68].
In BCC, it has been observed that tumour progression is accompanied by the decreased
membranous expression of E‐cadherin. Additionally, the increased nuclear localization of E‐
cadherin, as well as nuclear translocation of β‐catenin, has been shown [52].
Analysis of 227 tissue sections of MCC has revealed weak and mainly cytoplasmic staining for
E‐cadherin and there were no statistically significant differences in the immunoreactivity
between various tumour locations (primary, local or distant metastasis), suggesting that E‐
cadherin is not relevant for MCC progression [69].
The loss of E‐cadherin has been suggested to be a trigger of cancer progression especially
because of the reduced cell‐cell adhesion and possible stimulation of T cell factor (TCF)‐
regulated genes, responsible for proliferation and invasion (c‐myc, cyclin D1, fibronectin and
matrilysin), as an effect of released β‐catenin migration to nucleus [19]. The expression of E‐
cadherin is regulated by different transcription factors including grainyhead‐like 3 (Grl‐3)
factor, which has been shown to participate in the regulation of differentiation and migration
of epithelial cells during embryonic development. In normal human keratinocytes (HaCat) and
human SCC (A431) cells, the reverse correlation between Grl‐3 and E‐cadherin expression level
has been shown and the induced overexpression of Grl‐3 in A431 cells has led to the increased
motility and invasion of cancer cells as an effect of E‐cadherin down‐regulation [65].
Another transcription factor, regulating E‐cadherin expression, is Slug. Its presence has been
confirmed in multiple melanoma tissue sections, and higher expression has been attributed to
nevi than to primary or metastatic melanoma. Such observations have suggested that higher
Slug expression is required at the beginning of melanocyte neoplastic transformation but not
during melanoma progression. However, in melanocytes and melanoma cells cultured in
vitro, the exogenous expression of Slug has resulted in the down‐regulated expression of E‐
cadherin and up‐regulated expression of N‐cadherin and subsequently more efficient cellular
migration and invasion [70].
E‐cadherin regulatory potential has been attributed also to NOTCH receptors and their
signalling pathways. In a set of tissue samples from skin cancer and their adjacent normal skin,
the analysis of NOTCH expression has shown the up‐regulated receptor expression along with
increased Snail and decreased E‐cadherin expression in cancer tissue. Simultaneously, the up‐
regulation/inhibition of NOTCH signalling in A341 cells has resulted in changes in E‐cadherin
expression, decrease or increase, respectively. The observed effects of NOTCH alteration in
SCC have been mediated by Snail up‐regulation and subsequent E‐cadherin promoter
methylation [71].
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The experiments with induced E‐cadherin suppression in Ras‐transformed keratinocytes have
revealed the importance of E‐cadherin role in SCC neoplastic transformation. E‐cadherin
absence has increased Src activity leading to the up‐regulated expression of FAK that sup‐
ported the progression of tumour malignancy also by the following deregulation of E‐
cadherin‐dependent adhesion [72].
In melanoma, cadherin switch has been widely described but its molecular mechanism is still
not fully explained. To deal with this, Hao et al. [73] using a set of melanoma cell lines from
different stages of progression have analysed the expression profile of E‐ and N‐cadherin,
PI3K/PTEN pathway components and Snail, Slug and Twist transcription factors. They have
shown the correlation between the loss of PTEN activity and E‐ to N‐cadherin switch. The
observed cadherin changes have been regulated at the transcriptional level by Twist and Snail,
which activity in PTEN‐null cells was stimulated by constitutively active PI3K. It has also been
reported that the membranous localization of E‐cadherin is not controlled by PI3K/PTEN but
more likely depends on cadherin‐β‐catenin interaction [73]. The study on a vast range of
primary melanoma tissue samples has confirmed the correlation between down‐regulated
PTEN expression and ‘cadherin switch’. Additionally, this study has shown the linkage of these
markers with melanoma progression parameter, that is, Breslow thickness of primary tumours,
ulceration and tumour stage. The immunohistochemical detection of E‐ and N‐cadherin as
well as PTEN has been conducted and the statistical analysis of results has shown that E‐
cadherin, unlike N‐cadherin, possesses a predictor value. Low E‐cadherin expression level has
been correlated with a better survival prognosis, without relapses and distant metastasis [74].
Cadherin‐mediated adhesion is regarded as a dynamic process adapting to the epithelial tissue
remodelling during development and wound healing but also during carcinogenesis. Con‐
sidering this fact, the proteolytic cleavage of E‐cadherin has been suggested as a mechanism
of rapid adhesion changes. The role in E‐cadherin shedding has been attributed to different
ADAMs (a disintegrin‐like and metalloproteinase) and MMPs (matrix metalloproteinases)
[75]. As a result of its action, a decreased membranous E‐cadherin expression and an increased
level of 80‐kDa soluble E‐cadherin fragment (sE‐cadherin) in tumour microenvironment have
been reported in human SCC clinical tissue samples and SCC mouse model. Moreover, sE‐
cadherin binding with HER/IGF‐1R has been observed, and the consequent initiation of pro‐
oncogenic signalling, resulting in cancer cell migration, proliferation and invasion, has been
reported. Thus, the sE‐cadherin has been suggested as a potential therapeutic target in skin
cancer treatment [76]. The potential therapeutic value of anti‐sE‐cadherin antibody has been
suggested in SCC model PAM212 cell line. This antibody has inhibited tumour growth,
enhanced cell death and silenced the pro‐survival pathways by the inhibition of proto‐
oncogenes (RTKs, IAPs and MDM2) and stimulation of tumour suppressor genes (PTEN and
p53) [77].
The diagnostic usefulness of E‐cadherin expression changes has been determined for mela‐
noma versus Spitz tumours distinction (Spitz tumour; a benign cutaneous melanocytic
tumour). Such distinction is often problematic because of poor reproducibility of Spitz tumour
features and therefore unequivocally delineated diagnostic criteria. The obtained results have
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suggested that the quantitative differences rather than qualitative irregularities in E‐cadherin
immunoreactivity could have diagnostic potential [78].
Studies in a variety of melanoma cell lines have shown that the restoration of E‐cadherin
expression leads to the renewing of communication with keratinocytes and inhibition of
melanoma cells invasion [79]. E‐cadherin‐restored expression has also been observed in SCC
cells treated with flavonoids. Highly invasive A431‐III cells selected from the parental A341
cell line have been analysed. The invasive potential of A341‐III cells has been attributed to their
mesenchymal‐like phenotype resulting from ‘cadherin switch’. Cells have been treated with
plant flavonoids: luteolin and quercetin. They are known for their anticancer activity resulting
in the inhibition of cell growth, induction of apoptosis and differentiation, as well as the
diminution of tumour angiogenesis, cancer cells adhesion, invasion and metastasis. As an
effect, A341‐III cells have remodelled their morphology to more epithelial‐like. It was accom‐
panied by changes in the EMT markers expression level, including down‐regulation of N‐
cadherin and up‐regulation of E‐cadherin, leading to the renovation of the cell‐cell junctions.
Therefore, both flavonoids used have been suggested to have chemopreventive, anticancero‐
genic or chemotherapeutic activity, mainly through their EMT‐reverting potential [80].
2.3.2. P-cadherin
The role of P‐cadherin in carcinogenesis is ambiguous. It has been shown to promote the
invasive behaviour of cancer cells; however, in melanoma it has been reported as a tumour
growth suppressor [81]. Clinical data have shown that in general, melanocytic cells in com‐
pound nevi and melanomas express E‐ and P‐cadherins; however, a reduction in the expression
thereof has been observed in correlation to the depth of melanoma cells dermal localization.
It has been suggested that this loss represents melanoma cells’ adaptation to the changed
microenvironment of the dermis and makes them less dependent on microenvironmental
stimulation leading to the increased cell proliferation and melanoma progression [82].
Additionally, the potential usefulness of P‐cadherin as a prognostic marker for immunohisto‐
chemical detection and diagnosis in patients with primary melanoma of less than 2‐mm
tumour thickness has been suggested [83]. In melanoma, the alteration of P‐cadherin expres‐
sion in a tissue section of different stages has been shown together with its switch from
membranous to cytoplasmic localization. These changes have strongly correlated with
patient’s survival prognosis, suggesting P‐cadherin as a useful marker of melanoma progres‐
sion [84].
2.3.3. N-cadherin
The analysis of E‐, N‐ and P‐cadherin expression has been conducted in human MCCs and in
Merkel cells of the healthy epidermis. It has shown the high level of N‐cadherin expression in
all MCCs with a simultaneous lack of immunoreactivity in the healthy epidermis. The strong
E‐ and P‐cadherin positive reaction of Merkel cells and only partial positive immunoreaction
for both cadherins in MCCs have also been shown. These results have suggested that ‘cadherin
switch’ takes place also during Merkel cells neoplastic transformation. Additionally, the loss
of P‐cadherin expression in MCCs has been linked with a more advanced clinical stages, while
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its expression has been significantly more frequent in primary MCC [64]. The study of Vlahova
and co‐workers has shown the similarity in P‐cadherin immunoreactivity between primary
tumours and distance metastasis of MCCs, while the lymph node metastases have exhibited
a lower level of P‐cadherin expression. Additionally, the analysis suggested that the membra‐
nous expression of P‐cadherin in MCCs positively correlates with a prolonged survival
prognosis [85]. Depending on the expressed cadherin type, melanoma cells, compared to
melanocytes, have been shown to possess different preferences in cell‐cell communication.
Melanocytes interact mostly with their neighbouring keratinocytes, while melanoma cells
preferentially form their gap junction with fibroblasts and among themselves. It has also been
observed that gap junction could be established between melanoma cells and N‐cadherin
expressing endothelial cells, suggesting that the gap junction formation is rather dependent
on N‐cadherin expression than cell‐type‐specific [79]. N‐cadherin‐dependent heterotypic cell‐
cell adhesion has been described between fibroblasts and WM1205Lu melanoma cells with
Smad7 overexpression. In this model, cells have been arrested in their invasion abilities. It has
been suggested that the subsequent loss of N‐cadherin expression during the following steps
of melanoma progression may be a key factor for metastasis formation, because melanoma
cells by losing their interaction with fibroblasts become able to migrate to distant metastatic
sites, and after that N‐cadherin expression can be restored [86]. Additionally, the role of N‐
cadherin expression for primary (WM793, WM115) and malignant melanoma cells
(WM1205Lu, WM266‐4 cell lines) proliferation has been analysed with the use of specific N‐
cadherin siRNA. The observed decrease in N‐cadherin expression level up‐regulates the cell
cycle inhibitors p15, p16, p21 and p27 expression leading to cell cycle arrest in G1 phase and
significantly down‐regulates AKT, ERK and β‐catenin signalling, resulting in the inhibition of
cell proliferation [87].
2.3.4. T-cadherin
During malignant transformation of melanocytes, the expression of T‐cadherin on both mRNA
and protein levels decreases, mainly due to the repression of CDH13 promoter activity by
BRN2 transcription factor [36], and finally disappears in human malignant melanomas [88].
Down‐regulation of T‐cadherin expression is accompanied by a higher growth, proliferation,
migration and invasion of malignant cells in vitro. Re‐expression of T‐cadherin in human
melanoma cells, via stable transfection, draws back these effects in vitro and in a xenograft
mouse model in vivo [89]. Re‐expression of T‐cadherin also elevates the apoptotic rate of
melanoma cells in vitro through down‐regulation of AKT and FoxO3a, which is in turn
accompanied by the down‐regulation of anti‐apoptotic molecules BCL‐2, BCL‐x and clustering
from one site and deactivation of transcription factors CREB and AP‐1 from another site [90].
Furthermore, ectopic up‐regulated T‐cadherin sensitizes the apoptosis induced by treatment
with CD95/Fas antibody CH‐11 [90]. Contradictory results have been demonstrated for a fully
mouse model of melanoma, where up‐regulated T‐cadherin acted oppositely at the same time:
as a positive and a negative regulator of mouse melanoma development [91]. Namely, it has
been shown that the overexpression of T‐cadherin in B16F10 mouse melanoma promotes
primary tumour growth due to the recruitment of mesenchymal stromal cells, as well as
enhances cell motility, invasiveness and metastasis formation in BDF1 mice in parallel with the
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inhibition of neovascularization of primary melanoma sites [91]. This apparent discrepancy
has been explained by the recent study, which showed that in the species‐specific environment
T‐cadherin‐overexpressed melanoma cells up‐regulated the level of pro‐oncogenic integrins,
chemokines, adhesion molecules and extracellular matrix components, which in turn in‐
creased the invasive potential of tumour cells [92]. It is believed that T‐cadherin is an endog‐
enous suppressor of keratinocyte proliferation by delaying the G2/M phase progression [93].
It has been shown that T‐cadherin is also a suppressor of keratinocyte migration and invasion,
and the inactivation of T‐cadherin, through allelic loss or hypermethylation of a gene‐promoter
region, may induce keratinocyte‐derived aggressive epithelial tumours with high metastatic
potential [94]. Inverse correlations between T‐cadherin expression and pre‐cancerous (AK,
BD), benign (KA) and malignant skin diseases (invasive SCC and BCC) have been well
documented in immunohistochemical and in vitro studies [88, 95–98]. In other works, the
expression of T‐cadherin was found to be higher in superficial, nodular or infiltrative BCCs
[99] as well as in differentiated/primary SCCs [100] than in normal keratinocytes; however, it
was mainly restricted to the leading fronts of the tumours, where the up‐regulated T‐cadherin
induced a morphological spread and inhibited cell invasive potential [100]. It has been shown
that ectopic up‐regulation of T‐cadherin increased SCC cell‐matrix adhesiveness by promoting
the retention of both β1 integrin and epidermal growth factor receptor (EGFR) in lipid raft
domains, and by increasing integrin β1‐activation in parallel with the suppression of tyrosine
phosphorylation of EGFR [101, 102].
The molecular mechanisms underlying T‐cadherin function as a guardian maintaining a non‐
invasive phenotype of keratinocytes are different from those typically associated with EMT
and consist in the indirect negative regulation of EGFR pathway activity; gain or loss of T‐
cadherin expression switches EGFR signalling off or on, respectively. On the other hand, loss
of T‐cadherin in SCC may lead to ligand‐dependent EGFR hyperactivation and acquiring
invasive and aggressive phenotype [102]. It has been shown that co‐culture of SCC cells with
epithelial cells stimulated ECs to produce EGF [103], which in turn facilitated transendothelial
migration of T‐cadherin‐silenced cells, and their growth within the invaded stroma [104]. In
human A431 cells (SCC), EGF‐induced phosphorylation of EGFR and resulting downstream
signalling through p38MAPK, Erk1/2 and Rac1 contributed to the re‐localization of T‐cadherin
within the plasma membrane from dispersed to focused in intercellular junctions, where it
indirectly co‐localizes with activated EGFR. Being in complex with p‐EGFR, T‐cadherin acts
as an attenuator for EGFR signalling and its loss shifts the balance between Erk1/2‐p38MAPK
in favour of Erk1/2 activity [104]. In this way, plasma membrane‐associated T‐cadherin
functions as a regulatory factor, which promotes or represses EGF effects mediated by MAP
kinases.
2.3.5. Proteins interacting with cadherins
Cadherins as adhesion receptors are players in the interdependent adhesion network and it is
still an issue to decipher the mechanism of their direct interaction with other adhesion proteins.
Studies show that E‐ and N‐cadherins participate in the adhesion along with integrins and
their interaction with α2β1‐integrin has been examined in melanoma cell line and tissue
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microarray and tissue section. Simultaneous expression of E‐ and N‐cadherins with α2β1‐
integrin has been reported in numerous primary and metastatic melanoma cells, and the
differentiated localization of such complexes has been observed suggesting their independ‐
ency. It has also been suggested that α2β1‐integrin/N‐cadherin complex interplays in the
regulation of melanoma cells invasion and migration, while the α2β1‐integrin/E‐cadherin
complex affects cell‐cell adhesion [105].
Another receptor cross‐talking with E‐cadherin is EGFR, which overexpression has been
commonly reported in many types of cancer, including skin cancer, and this interaction is of
particular interest regarding tumour progression. The association between both receptors is
realized via domain of β‐catenin, which has been shown to participate in ligand‐induced E‐
cadherin signalling resulting in the inhibition of EGF‐dependent cell growth. It has been
suggested that homophilic binding of E‐cadherin interrupts the activation‐signalling pathway
subsequent to EGFR without blocking receptor activation [106]. On the other hand, activated
EGFR has been described as an upstream regulator of Twist expression leading to its overex‐
pression and alternating E‐cadherin down‐regulation together with EMT of SCC cells. These
observations have suggested mutual regulation between E‐cadherin and EGFR [107]. Addi‐
tionally, the analysis of head and neck SCC has revealed that E‐cadherin loss is accompanied
by the transcriptional up‐regulation of EGFR and results in the increased cell proliferation due
to enhanced EGFR signalling [108]. EGFR has also been reported to regulate E‐cadherin‐
dependent cell‐cell adhesion by the modulation of E‐cadherin assembly with actin cytoskele‐
ton and vinculin, and EGFR activation has led to the distraction of cadherin‐vinculin‐actin
complexes [109].
Interesting interaction has also been described between E‐cadherin and caveolin‐1, which is
generally recognized as a tumour suppressor; however, its contribution to metastasis forma‐
tion has also been described. In melanoma cells, the co‐expression and observed co‐localization
of E‐cadherin and caveolin‐1 have resulted in the decreased cell proliferation, enhanced cell
death and reduced subcutaneous tumour growth. Despite the reduced E‐cadherin expression,
related with ‘cadherin switch’ occurring in melanoma progression, caveolin‐1 expression has
increased in the analysed metastatic melanomas and correlated with higher tumour malig‐
nancy. Due to collectively observed N‐cadherin expression, their potential cooperation with
caveolin‐1 in lung metastasis formation has been suggested [110].
3. Alterations in glycophenotype of cells in skin cancers
Nowadays, instead of the conventional histopathological diagnosis, the antibody or lectin
histochemistry approaches are used to distinguish between normal, pre‐neoplastic, benign
and malignant skin tissues and to improve a quantitative assessment of cancer progression
[111]. For example, AK, KA, SCC and BCC show lower expression of high mannose‐type
and/or hybrid‐type N‐glycans as well as fucose α1,2‐linked to galactose residue (H antigen)
compared to normal tissue. However, cutaneous tumours (SCC, BCC, invasive melanoma)
display higher expression of truncated mucin‐type O‐glycan, that is, T antigen (Galβ1‐3Gal‐
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NAc residue) than normal tissue [111–113]. Mannose‐type and/or hybrid‐type N‐glycans
and T antigen can be used as markers for the distinction between BCC and TE [111]. Higher‐
expression levels of β‐galactoside α‐2,3 sialyltransferase (ST3Gal I) and higher cell‐surface
reactivity with Maackia amurensis agglutinin (MAA), which recognizes sialic acid α2,3‐linked
to Gal residue, allow to distinguish AK and SCC from KA, BCC and normal epidermis [113,
114]. MCCs do not show expression of neither α2,3‐linked sialic acid nor H antigen [115]. By
contrast, the expression of β‐galactoside α‐2,6‐sialyltransferase (ST6Gal I) is higher in skin
tumours with a greater potential for invasion and metastasis, as in the case of SCC, BCC and
melanoma [114, 116]. The difference in the expression level of α2,6‐linked sialic acid distin‐
guishes premalignant AK stage from the invasive SCC stage of skin cancer. Unlike the nor‐
mal and non‐malignant epidermis, pre‐malignant biopsies and malignant cells from patients
with BCC and SCC are positive with the sialylated Lea structure [117]. Additional O‐acetyla‐
tion at C‐9 of sialic acid residue is prominent in melanoma and BCC [116]. It has been shown
that very intense binding of mistletoe lectin I (ML‐I; which is specific for galactose and
Neu5Acα2‐6Galβ‐) and of Helix pomatia agglutinin (HPA; it selectively binds to T and Tn an‐
tigens) was positively correlated with the metastasis of melanoma and were not expressed in
benign nevus cells, and thus they are predictors of poor prognosis [118–120].
4. Glycosylation of cadherins the skin cancers
Cadherins, like other adhesion proteins, are strongly glycosylated, as they possessed a number
of potential N‐glycosylation sites in their extracellular domain and O‐glycosylation sites in the
cytoplasmic domain. Based on the analysis of amino acid sequence, human E‐cadherin
possesses four potential N‐glycosylation sites in its extracellular domain, located at Asn
residues 554, 566, 618 and 633 [28], in EC4 and EC5 [121]. N‐cadherin ectodomain has been
reported to contain eight potential N‐glycosylation sites, but only three of them, located in EC2
and EC3, were effectively N‐glycosylated [122].
Despite the described redundancy of possible N‐glycosylation sites, it has been shown that up
to 20% of total molecular mass of cadherin may come from the N‐glycan component, and it is
the most prominent cadherin post‐translational modification. In a culture, more abundant N‐
glycosylation of E‐cadherin has been observed in sparsely growing cells than in dense ones.
E‐cadherin from sparse cultures has been shown to possess mainly complex‐type and lack the
high mannose‐type N‐glycans. On the contrary, N‐glycans of E‐cadherin from cells growing
in a dense culture have composed mainly of high mannose‐type and only small amounts of
complex‐type N‐glycans have been detected. Furthermore, the differences in E‐cadherin
turnover have been reported in respect to its glycosylation status. In general, the level of E‐
cadherin expression in a dense culture is lowered. Also, the constitution and stability of AJs
have been affected by E‐cadherin changed N‐glycans structure and quantity. The high level of
E‐cadherin N‐glycosylation in a sparse culture has led to unstable adhesion and it has been
correlated with cell proliferation. On the other hand, in a dense culture, E‐cadherin decoration
with high mannose‐type N‐glycans has resulted in the formation of stable AJs and stronger
adhesion [10].
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Aberrations in N‐oligosaccharides composition are also commonly attributed to cancer
transformation and progression in various types of cancer cells [123]. The biantennary
complex‐type and high mannose‐type oligosaccharides are characteristic for normal cells,
while progressive malignant transformation of cancer cells is accompanied by the synthesis of
more branched (tri‐, tetra‐ or even pentaantennary) N‐glycans of complex‐types, elongated
with poly‐N‐acetyllactosamine chains [124].
There are also some data concerning the abundance and diverse structural composition of N‐
glycans attached to cadherin observed mostly in melanoma among other skin cancers [125–
128] and N‐glycosylation role in cadherin function has been confirmed [29]. O‐glycosylation
of cadherins has also been described, and especially concerning E‐cadherin, their role in the
inhibition of protein trafficking has been suggested [129].
Figure 1. N‐glycan structures detected on N‐cadherin in melanoma. Gal, galactose; GlcNAc, N‐acetylglucosamine; Fuc,
fucose; Man, mannose; and SA, sialic acids.
The changed N‐glycosylation of cadherins (E‐ and N‐cadherin) has been described in mela‐
noma cells of various cell lines [126–128, 130]. However, this problem has not been studied as
extensively as in other types of cancer. The detailed N‐glycans analysis showed that N‐cadherin
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from primary melanoma cells possesses mainly high mannose‐type and biantennary complex‐
type oligosaccharides with α2,6‐linked sialic acids, while N‐cadherin from metastatic cells
possesses mostly tri‐ and tetraantennary complex‐type oligosaccharides, with β1,6‐branches,
highly α‐fucosylated and with α2,3‐linked sialic acids (Figure 1) [126, 128, 130]. Such obser‐
vations are in line with observations that more branched N‐glycans, especially β1,6‐branched
oligosaccharides, are associated with a higher motility of tumour cells and its more invasive
behaviour. In mouse melanoma model B16F10 cells, E‐cadherin was shown to be a target
protein for N‐acetylglucosaminyltransferase III (GnT‐III) action, which is suggested to be a
suppressor of the invasive phenotype. In GnT‐III‐transfected melanoma cells, E‐cadherin has
been found to bear the bisecting GlcNAc structures which prolonged E‐cadherin turnover and
resistance to proteolysis. As an effect, the enhancement of cadherin‐dependent cellular
adhesion leading to the suppression of metastasis has been observed [125].
5. Conclusions
It is commonly accepted that cadherins play a crucial role in cancer progression. Their
expression abnormality taking place in different stages of skin cancer progression as well as
changes in their glycosylation status leading to adhesion impairment precedes tumour cells
dissemination and metastasis formation. The detailed analysis of cadherin‐related glycosy‐
lation changes in cancer cells could be a key for better understanding of the nature of
malignant transformation process and may open new opportunities for the development of
more effective anticancer therapeutics and diagnostic tools.
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